Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | BMP1 | P13497 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117317 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1TAS2R14MAPTBMP1 | |
| SCHEMBL5122060 | 0.91 | KDM4E (0.53) | KDM4EALDH1A1TAS2R14MAPTBMP1 | |
| SCHEMBL5122055 | 0.91 | KDM4E (0.53) | KDM4EALDH1A1TAS2R14MAPTBMP1 | |
| SCHEMBL5122191 | 0.90 | TAS2R14 (0.53) | ALDH1A1TAS2R14 | |
| SCHEMBL5119869 | 0.90 | PSEN1 (0.46) | KDM4EALDH1A1TAS2R14BMP1NR3C1 | |
| SCHEMBL5119864 | 0.90 | PSEN1 (0.46) | KDM4EALDH1A1TAS2R14BMP1NR3C1 | |
| SCHEMBL5113920 | 0.90 | KDM4E (0.45) | KDM4EALDH1A1TAS2R14MAPTBMP1 | |
| SCHEMBL5113926 | 0.90 | KDM4E (0.45) | KDM4EALDH1A1TAS2R14MAPTBMP1 | |
| SCHEMBL5121062 | 0.89 | MAPT (0.54) | KDM4EALDH1A1TAS2R14MAPTBMP1 | |
| SCHEMBL5121059 | 0.89 | MAPT (0.54) | KDM4EALDH1A1TAS2R14MAPTBMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747195-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2007-01-31 | — | — | EP | claimed |
| US-7163942-B2 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2007-01-16 | — | — | US | claimed |
| WO-2005095334-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20050222254-A1 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | claimed |
| US-7345095-B2 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070129349-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC | 2007-06-07 | — | — | US | disclosed |
| EP-1747195-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2007-01-31 | — | — | EP | disclosed |
| US-7163942-B2 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2007-01-16 | — | — | US | disclosed |
| WO-2005095334-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222254-A1 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129349-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PSEN1, APP, PSEN2 | KDM4E 3685/4885ALDH1A1 1291/4885TAS2R14 1345/4885 |
| US-20050222254-A1 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PSEN1, APP, PSEN2 | KDM4E 3671/4885ALDH1A1 1386/4885TAS2R14 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.